The role of soy isoflavones in menopausal health: Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010)

Thomas B. Clarkson, Wulf H. Utian, Stephen Barnes, Ellen B. Gold, Shehzad S. Basaria, Takeshi Aso, Fredi Kronenberg, Cara L. Frankenfeld, J. M Ark Cline, Britt Marie Landgren, John Christopher G. Gallagher, Connie M. Weaver, Howard N. Hodis, Roberta Diaz Brinton, Pauline M. Maki, Kenneth D R Setchell, D. R. Setchell, Tara I. Allmen, Mark J. Messina, Xiao Ou ShuYoshiko Ishimi, William W. Wong, Helen Kim

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Objectives: If and to what extent soy protein, soy isoflavones, and their metabolites, including S(-)-equol, have beneficial effects on women's health is currently unclear. The North American Menopause Society (NAMS)/Utian Translational Science Symposium on Soy and Soy Isoflavones convened October 9-10, 2010, to clarify basic and clinical research findings as they relate to the risk and benefits of soy products for peri- and postmenopausal women. Methods: A working group of faculty and panelists composed of clinical and research experts in the fields of women's health and botanicals met during a 2-day translational symposium to cover the latest evidence-based science on isoflavones as they affect menopausal symptoms, breast and endometrial cancer, atherosclerosis, bone loss, and cognition. Full descriptions of the bioavailability and pharmacokinetics of isoflavones were also presented. Subspecialty groups then broke off with the goal of translating the information into a report for general medical practice and identifying further research areas. All faculty and panelists reviewed the final report, which was then approved by the NAMS Board of Trustees. Results: From the hundreds of studies reviewed in this report, there are mixed results of the effects on midlife women. Soy-based isoflavones are modestly effective in relieving menopausal symptoms; supplements providing higher proportions of genistein or increased in S(-)-equol may provide more benefits. Soy food consumption is associated with lower risk of breast and endometrial cancer in observational studies. The efficacy of isoflavones on bone has not been proven, and the clinical picture of whether soy has cardiovascular benefits is still evolving. Preliminary findings on cognitive benefit from isoflavone therapy support a "critical window" hypothesis wherein younger postmenopausal women derive more than older women. Conclusions: Several areas for further research have been identified on soy and midlife women. More clinical studies are needed that compare outcomes among women whose intestinal bacteria have the ability to convert daidzein to equol (equol producers) with those that lack that ability (equol nonproducers) in order to determine if equol producers derive greater benefits from soy supplementation. Larger studies are needed in younger postmenopausal women, and more research is needed to understand the modes of use of soy isoflavone supplements in women. The interrelations of other dietary components on soy isoflavones consumed as a part of diet or by supplement on equol production also require further study, as do potential interactions with prescription and over-the-counter medications. And finally, greater standardization and documentation of clinical trial data of soy are needed.

Original languageEnglish
Pages (from-to)732-753
Number of pages22
JournalMenopause
Volume18
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Isoflavones
Equol
Health
Research
Aptitude
Women's Health
Endometrial Neoplasms
Breast Neoplasms
Soy Foods
Trustees
Bone Neoplasms
Soybean Proteins
Genistein
Menopause
General Practice
Documentation
Cognition
Biological Availability
Observational Studies
Prescriptions

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

The role of soy isoflavones in menopausal health : Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). / Clarkson, Thomas B.; Utian, Wulf H.; Barnes, Stephen; Gold, Ellen B.; Basaria, Shehzad S.; Aso, Takeshi; Kronenberg, Fredi; Frankenfeld, Cara L.; Cline, J. M Ark; Landgren, Britt Marie; Gallagher, John Christopher G.; Weaver, Connie M.; Hodis, Howard N.; Brinton, Roberta Diaz; Maki, Pauline M.; Setchell, Kenneth D R; Setchell, D. R.; Allmen, Tara I.; Messina, Mark J.; Shu, Xiao Ou; Ishimi, Yoshiko; Wong, William W.; Kim, Helen.

In: Menopause, Vol. 18, No. 7, 07.2011, p. 732-753.

Research output: Contribution to journalArticle

Clarkson, TB, Utian, WH, Barnes, S, Gold, EB, Basaria, SS, Aso, T, Kronenberg, F, Frankenfeld, CL, Cline, JMA, Landgren, BM, Gallagher, JCG, Weaver, CM, Hodis, HN, Brinton, RD, Maki, PM, Setchell, KDR, Setchell, DR, Allmen, TI, Messina, MJ, Shu, XO, Ishimi, Y, Wong, WW & Kim, H 2011, 'The role of soy isoflavones in menopausal health: Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010)', Menopause, vol. 18, no. 7, pp. 732-753. https://doi.org/10.1097/gme.0b013e31821fc8e0
Clarkson, Thomas B. ; Utian, Wulf H. ; Barnes, Stephen ; Gold, Ellen B. ; Basaria, Shehzad S. ; Aso, Takeshi ; Kronenberg, Fredi ; Frankenfeld, Cara L. ; Cline, J. M Ark ; Landgren, Britt Marie ; Gallagher, John Christopher G. ; Weaver, Connie M. ; Hodis, Howard N. ; Brinton, Roberta Diaz ; Maki, Pauline M. ; Setchell, Kenneth D R ; Setchell, D. R. ; Allmen, Tara I. ; Messina, Mark J. ; Shu, Xiao Ou ; Ishimi, Yoshiko ; Wong, William W. ; Kim, Helen. / The role of soy isoflavones in menopausal health : Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). In: Menopause. 2011 ; Vol. 18, No. 7. pp. 732-753.
@article{b602259c650a4b588096a4d5edb8a7ff,
title = "The role of soy isoflavones in menopausal health: Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010)",
abstract = "Objectives: If and to what extent soy protein, soy isoflavones, and their metabolites, including S(-)-equol, have beneficial effects on women's health is currently unclear. The North American Menopause Society (NAMS)/Utian Translational Science Symposium on Soy and Soy Isoflavones convened October 9-10, 2010, to clarify basic and clinical research findings as they relate to the risk and benefits of soy products for peri- and postmenopausal women. Methods: A working group of faculty and panelists composed of clinical and research experts in the fields of women's health and botanicals met during a 2-day translational symposium to cover the latest evidence-based science on isoflavones as they affect menopausal symptoms, breast and endometrial cancer, atherosclerosis, bone loss, and cognition. Full descriptions of the bioavailability and pharmacokinetics of isoflavones were also presented. Subspecialty groups then broke off with the goal of translating the information into a report for general medical practice and identifying further research areas. All faculty and panelists reviewed the final report, which was then approved by the NAMS Board of Trustees. Results: From the hundreds of studies reviewed in this report, there are mixed results of the effects on midlife women. Soy-based isoflavones are modestly effective in relieving menopausal symptoms; supplements providing higher proportions of genistein or increased in S(-)-equol may provide more benefits. Soy food consumption is associated with lower risk of breast and endometrial cancer in observational studies. The efficacy of isoflavones on bone has not been proven, and the clinical picture of whether soy has cardiovascular benefits is still evolving. Preliminary findings on cognitive benefit from isoflavone therapy support a {"}critical window{"} hypothesis wherein younger postmenopausal women derive more than older women. Conclusions: Several areas for further research have been identified on soy and midlife women. More clinical studies are needed that compare outcomes among women whose intestinal bacteria have the ability to convert daidzein to equol (equol producers) with those that lack that ability (equol nonproducers) in order to determine if equol producers derive greater benefits from soy supplementation. Larger studies are needed in younger postmenopausal women, and more research is needed to understand the modes of use of soy isoflavone supplements in women. The interrelations of other dietary components on soy isoflavones consumed as a part of diet or by supplement on equol production also require further study, as do potential interactions with prescription and over-the-counter medications. And finally, greater standardization and documentation of clinical trial data of soy are needed.",
author = "Clarkson, {Thomas B.} and Utian, {Wulf H.} and Stephen Barnes and Gold, {Ellen B.} and Basaria, {Shehzad S.} and Takeshi Aso and Fredi Kronenberg and Frankenfeld, {Cara L.} and Cline, {J. M Ark} and Landgren, {Britt Marie} and Gallagher, {John Christopher G.} and Weaver, {Connie M.} and Hodis, {Howard N.} and Brinton, {Roberta Diaz} and Maki, {Pauline M.} and Setchell, {Kenneth D R} and Setchell, {D. R.} and Allmen, {Tara I.} and Messina, {Mark J.} and Shu, {Xiao Ou} and Yoshiko Ishimi and Wong, {William W.} and Helen Kim",
year = "2011",
month = "7",
doi = "10.1097/gme.0b013e31821fc8e0",
language = "English",
volume = "18",
pages = "732--753",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - The role of soy isoflavones in menopausal health

T2 - Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010)

AU - Clarkson, Thomas B.

AU - Utian, Wulf H.

AU - Barnes, Stephen

AU - Gold, Ellen B.

AU - Basaria, Shehzad S.

AU - Aso, Takeshi

AU - Kronenberg, Fredi

AU - Frankenfeld, Cara L.

AU - Cline, J. M Ark

AU - Landgren, Britt Marie

AU - Gallagher, John Christopher G.

AU - Weaver, Connie M.

AU - Hodis, Howard N.

AU - Brinton, Roberta Diaz

AU - Maki, Pauline M.

AU - Setchell, Kenneth D R

AU - Setchell, D. R.

AU - Allmen, Tara I.

AU - Messina, Mark J.

AU - Shu, Xiao Ou

AU - Ishimi, Yoshiko

AU - Wong, William W.

AU - Kim, Helen

PY - 2011/7

Y1 - 2011/7

N2 - Objectives: If and to what extent soy protein, soy isoflavones, and their metabolites, including S(-)-equol, have beneficial effects on women's health is currently unclear. The North American Menopause Society (NAMS)/Utian Translational Science Symposium on Soy and Soy Isoflavones convened October 9-10, 2010, to clarify basic and clinical research findings as they relate to the risk and benefits of soy products for peri- and postmenopausal women. Methods: A working group of faculty and panelists composed of clinical and research experts in the fields of women's health and botanicals met during a 2-day translational symposium to cover the latest evidence-based science on isoflavones as they affect menopausal symptoms, breast and endometrial cancer, atherosclerosis, bone loss, and cognition. Full descriptions of the bioavailability and pharmacokinetics of isoflavones were also presented. Subspecialty groups then broke off with the goal of translating the information into a report for general medical practice and identifying further research areas. All faculty and panelists reviewed the final report, which was then approved by the NAMS Board of Trustees. Results: From the hundreds of studies reviewed in this report, there are mixed results of the effects on midlife women. Soy-based isoflavones are modestly effective in relieving menopausal symptoms; supplements providing higher proportions of genistein or increased in S(-)-equol may provide more benefits. Soy food consumption is associated with lower risk of breast and endometrial cancer in observational studies. The efficacy of isoflavones on bone has not been proven, and the clinical picture of whether soy has cardiovascular benefits is still evolving. Preliminary findings on cognitive benefit from isoflavone therapy support a "critical window" hypothesis wherein younger postmenopausal women derive more than older women. Conclusions: Several areas for further research have been identified on soy and midlife women. More clinical studies are needed that compare outcomes among women whose intestinal bacteria have the ability to convert daidzein to equol (equol producers) with those that lack that ability (equol nonproducers) in order to determine if equol producers derive greater benefits from soy supplementation. Larger studies are needed in younger postmenopausal women, and more research is needed to understand the modes of use of soy isoflavone supplements in women. The interrelations of other dietary components on soy isoflavones consumed as a part of diet or by supplement on equol production also require further study, as do potential interactions with prescription and over-the-counter medications. And finally, greater standardization and documentation of clinical trial data of soy are needed.

AB - Objectives: If and to what extent soy protein, soy isoflavones, and their metabolites, including S(-)-equol, have beneficial effects on women's health is currently unclear. The North American Menopause Society (NAMS)/Utian Translational Science Symposium on Soy and Soy Isoflavones convened October 9-10, 2010, to clarify basic and clinical research findings as they relate to the risk and benefits of soy products for peri- and postmenopausal women. Methods: A working group of faculty and panelists composed of clinical and research experts in the fields of women's health and botanicals met during a 2-day translational symposium to cover the latest evidence-based science on isoflavones as they affect menopausal symptoms, breast and endometrial cancer, atherosclerosis, bone loss, and cognition. Full descriptions of the bioavailability and pharmacokinetics of isoflavones were also presented. Subspecialty groups then broke off with the goal of translating the information into a report for general medical practice and identifying further research areas. All faculty and panelists reviewed the final report, which was then approved by the NAMS Board of Trustees. Results: From the hundreds of studies reviewed in this report, there are mixed results of the effects on midlife women. Soy-based isoflavones are modestly effective in relieving menopausal symptoms; supplements providing higher proportions of genistein or increased in S(-)-equol may provide more benefits. Soy food consumption is associated with lower risk of breast and endometrial cancer in observational studies. The efficacy of isoflavones on bone has not been proven, and the clinical picture of whether soy has cardiovascular benefits is still evolving. Preliminary findings on cognitive benefit from isoflavone therapy support a "critical window" hypothesis wherein younger postmenopausal women derive more than older women. Conclusions: Several areas for further research have been identified on soy and midlife women. More clinical studies are needed that compare outcomes among women whose intestinal bacteria have the ability to convert daidzein to equol (equol producers) with those that lack that ability (equol nonproducers) in order to determine if equol producers derive greater benefits from soy supplementation. Larger studies are needed in younger postmenopausal women, and more research is needed to understand the modes of use of soy isoflavone supplements in women. The interrelations of other dietary components on soy isoflavones consumed as a part of diet or by supplement on equol production also require further study, as do potential interactions with prescription and over-the-counter medications. And finally, greater standardization and documentation of clinical trial data of soy are needed.

UR - http://www.scopus.com/inward/record.url?scp=79959723419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959723419&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e31821fc8e0

DO - 10.1097/gme.0b013e31821fc8e0

M3 - Article

C2 - 21685820

AN - SCOPUS:79959723419

VL - 18

SP - 732

EP - 753

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 7

ER -